Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.14), $0.07 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $53.81 million versus the consensus estimate of $53.8 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.